TELO (Telomir Pharmaceuticals) ROE % Adjusted to Book Value : -11.41% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals ROE % Adjusted to Book Value?

Telomir Pharmaceuticals's ROE % for the quarter that ended in Dec. 2024 was -2,136.77%. Telomir Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2024 was 187.27. Telomir Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -11.41%.

Telomir Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Telomir Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals ROE % Adjusted to Book Value Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

-4.33

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial							-	-15.35	-2.79	-5.57	-11.41

Competitive Comparison of Telomir Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Telomir Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telomir Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Telomir Pharmaceuticals ROE % Adjusted to Book Value Calculation

Telomir Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-810.24%	/	187.27
	=	-4.33%

Telomir Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-2,136.77%	/	187.27
	=	-11.41%

Telomir Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 South East, 2nd Street, Suite 200, No.1009, Miami, FL, USA, 33131

Website

https://www.telomirpharma.com

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.